Clinical Trial Update: Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116 [Phase 1]

View source ↗

Summary

A Phase 1 first-in-human study of BAY1161116 evaluating safety, tolerability, and pharmacokinetics in polycystic ovary syndrome has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycystic Ovary Syndrome

Drugs mentioned

• BAY1161116

Snippet

Sponsor: Bayer | Conditions: Polycystic Ovary Syndrome | Phase 1 | Status: TERMINATED